Arcus Biosciences Inc
RCUSHealthcare|Biotechnology|USA
$28.92
-1.04 (-3.47%)
Tangible Book
$4.18
Upcoming Data Readouts (22)
Aug 2026
Est. completion
P2Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565n=100
Oct 2026
Est. completion
P2Non Small Cell Lung Cancer
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
NCT04791839n=30
Nov 2026
Est. completion
P1Advanced Cancer
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075n=91
Dec 2026
Est. completion
P1P2Borderline Resectable Pancreatic Adenocarcinoma
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT05688215n=56
Dec 2026
Est. completion
P2Rectal Cancer
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
NCT05024097n=43
Dec 2026
Est. completion
P2Oligometastatic Prostate Cancer
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT05915442n=23
Jan 2027
Est. completion
P2Gastrointestinal Tract Malignancies
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766n=332
Apr 2027
Est. completion
P2Pancreatic Ductal Adenocarcinoma
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
NCT06048484n=60
Apr 2027
Est. completion
P2Prostate Adenocarcinoma
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT03821246n=68
May 2027
Est. completion
P2Non Small Cell Lung Cancer
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173n=169
May 2027
Est. completion
P1Advanced Pancreatic Cancer
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
NCT04104672n=196
Sep 2027
Est. completion
P1Advanced Cancer
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171n=40
Dec 2027
Est. completion
P2Advanced Non-Small Cell Lung Cancer
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931n=400
Dec 2027
Est. completion
Jan 2028
Est. completion
P2Renal Cell Carcinoma
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
NCT07397611n=32
Apr 2028
Est. completion
P3Metastatic Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719n=720
Jun 2028
Est. completion
P3Non-small Cell Lung Cancer
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237n=1,021
Jul 2028
Est. completion
P3Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895n=860
Mar 2029
Est. completion
P1Clear Cell Renal Cell Carcinoma
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141n=362
Sep 2029
Est. completion
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Jul 2026
P2
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
NCT06048133Jun 2026
P3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095Feb 2026
P2
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
NCT05130177